Brief: Aravive Inc - Received Guidance From U.S FDA On Phase 3 Trial Design For Avb-500 In Platinum Resistant Ovarian Cancer

Aravive

19/11/2020 12:31

Nov 19 (Reuters) - Aravive Inc  ARAV.O :
    * ARAVIVE INC - RECEIVED GUIDANCE FROM U.S FDA ON PHASE 3
TRIAL
DESIGN FOR AVB-500 IN PLATINUM RESISTANT OVARIAN CANCER
    * ARAVIVE INC - PLAN TO INITIATE AVB-500 PHASE-3 TRIAL IN Q1
OF
2021, WITH AN INTERIM ANALYSIS EXPECTED A YEAR LATER
    * ARAVIVE INC - PHASE 3 TRIAL IS EXPECTED TO ENROLL ABOUT
300-400
PATIENTS WITH HIGH-GRADE SEROUS OVARIAN CANCER

Source text for Eikon:  ID:nGNX9LNrK0 
Further company coverage:  ARAV.O 

 ((Reuters.Briefs@thomsonreuters.com;))